myland to buy perigo. one of the top shellers of the generic medications and fu mid sized drug firms. perigo said it will meet to discuss the offer with its board. higher by 3% and shares of mailan up. these were the first and second best performing stocks inside the s&p 500 index respectively today. >>> well tonight marks the unofficial start of earnings season with a late report from aluminum maker alcoa. per tradition, the company earned adjusted 28% of shares beat estimates by 2% but revenue came a little shy of expectations but it was still higher than a year ago. shares fell initially in the after hours trade. morgan brennan joins us now with one of the key takeaways from alcoa's earnings. good evening. good evening, bill. yeah so it was mixed results with shares about alcoa trade after hours as a result of that. that said this was a solid quarter for this company. we saw record results in upstream metals business. the smelting of aluminum, better than expected and we continue to see this transition

mylan for perigo teva for mylan. value creating combination between teva and mylan.se remember it's $82 a share in cash and stock and they say that they remain fully committed to getting that deal done as i pointed out many times, they may be fully committed but there are a great deal of weapons in the arsenal that mylan has to prevent them from being successful. not the least of which is the structure in netherlands. and mylan has yet it even respond to teva's offer. typically we would get some sort of response from mylan. remember it came out prior to the actual offer and said it wasn't interested. before teva even made it. >>> shares of juniper networks are soaring are up on soaring earnings. juniper's new ceo after his predecessor was force to resign in november following a board review of his conduct with an unnamed client. joining us, the ceo of juniper networks. good morning to you. it looks like the quarter was all about demand for the cloud, cable and the european telcos. >> you're right. we had a solid q 1 quarter. think that's a testament to the fact that

mylan went forward with a hostile bid for fellow drugmaker perigo taking the offer directly to shareholdersher than accepting a separate takeover proposal. it argues it is not as high as it seems because mylan stock has been inflated by teva's takeover offer offering to buy it for $40 billion this week. hsbc says it may move its headquarters out of the u.k. the reason, rising tax and regulatory costs. hsbc could end up in hong kong, a logical place since the formal title is the hong kong and shanghai banking corporation. politics may be involved as it is less than two weeks before the british election. hsbc might be trying to pressure politicians. john boehner says hillary clinton is a good public servant but she has explaining to do about the way she handled official e-mails as secretary of state. he spoke in an exclusive interview with "all due respect." john boehner: she violated the law and the idea she was going to use her own server and do official business on it has every transparency issue the president likes to tout. mark: speaker boehner also said both clintons need to explain the

a generic drugmaker has offered to buy a pair ago -- perigo. that represents a 25% premium over tuesday's closing price. that would add to a record time of consolidation in the pharmasset goal industry. last year, they acquired abbott laboratories in their non-u.s. locations as part of a plan to move its tax address to the netherlands. it is the biggest deal in the oil and gas industry in at least a decade -- royal dutch shell will buy bg group for $70 billion in cash and stocks. that represents a premium of 50% on their closing price yesterday. the shell ceo told bloomberg that the deal is a bargain. >> the way we would look at it is if you look at the combination of the two companies, what we can do with the fantastic assets bg has with our capabilities applied to them, we saw a lot more value in that combination than the market. mark: the combined company would surpass chevron as the second-largest oil and gas producer after exxon mobil and would be able to get rid of overlapping costs to offset the impact of lower oil prices. a white police

we have milan proposing to buy perigo. meg is at hq. >> that's right.es, mylan proposing to acquire perrigo for $205 a share, cash and mylan stock, mylan is saying represents a greater than 25% premium to perrigo's trading price as of the close of business on friday april 3rd. now again this is a proposal and mylan is saying in this release now that it's a culmination of a number of prior discussions. the two companies have had. now these are both companies that sell generic and over the counter products and this would combine two big companies making a bigger one here. this is just a proposal, $205 a share, mylan proposing to buy perrigo. back to you. >> apparently in the letter they've had discussions over the past few years which they note in the letter. we did see trading ahead of the news before halted. not often we get a $30 billion proposal in the middle of the market day. thank you very much for that. >>> lauren, back to you. i guess separate from the review, what kind of expectations do you have in terms of apple watch sales as it heads towards

. >> perigo rejecting mylan's offer made in cash and stock that would have valued the over-the-countericines maker at $32 million. perrigo said the offer is below a prior proposal based on unaffected mylan stock price and that shareholders are strongly advised to take no action in relation to the offer. getting all of this as mylan itself is trying to fend off a takeover bid from teva pharmaceutical, which recently made $43 billion for mylan. so shares of perrigo down 3%. shares of mylan down 2.5% and shares of teva up 1%. >> a quick note that the m&a activity in the health care space and the biotech and pharma world continues apace and that's why for all of us talking about a bubble or lofty valuations in biotech, that's why they stay at these levels. m&a activity. >> enough to own something like an ivb or -- >> that's a great question and it's a different question. no, i would not be buying these here at these valuations, but i'm just explaining why they haven't come down. after months, many months of us talking about this. >>> coming up, debating tractor supply, the company beating

you've got insight into the mylan/perigo -- >> the cold and flu season wasn't strong.s in supplements. this united states a company, i think, is uniquely undervalued by the market. the structure was difficult to understand. i think that it makes a great deal of sense for mylan to do it. it joins acty vift. it's where all of the action is focused on another one, a takeover target in a couple of months. >> been a while, maybe somebody else comes in here too. remember we had gulf and stuff, the good old days they kept coming back and the other one would come back? >> people should be excited. you know it i know it. they should be saying, wow, i can believe we've got a stock up 30. people saying i guess i can't catch those. or i've got to be in an etf in oil. and they're missing great opportunities whether it be with apple or perrigo, accessible ideas. >> watching the masters? it's not your thing? >> this weekend's when i kick it. i always watch it. we put it on. look it's in the background until the last day, boy, yeah anyone who doesn't watch it? honestly. >> looking at